Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described.

中文翻译：

---

卡博替尼治疗转移性肾细胞癌的体重和骨骼肌损失

卡博替尼是一种标准治疗转移性肾细胞癌 (mRCC)，可能与体重和肌肉损失有关。新一代 VEGFR 酪氨酸激酶抑制剂对肌肉质量损失的这些影响描述得很少。